36
Participants
Start Date
August 26, 2022
Primary Completion Date
June 13, 2025
Study Completion Date
October 31, 2025
inupadenant
Adenosine 2a receptor antagonist
Placebo
matched placebo capsule to inupadenant
Carboplatin
standard of care chemotherapeutic, alkylating agent
Pemetrexed
standard of care chemotherapeutic, anti-metabolite
Centre Hospitalier Universitaire Vaudois, Lausanne
Jessa Ziekenhuis, Hasselt
AZ Delta, Roeselare
Algemeen Ziekenhuis Sint-Lucas, Ghent
Complejo Hospitalario Universitario de Ourense, Ourense
Hopital de la Timone Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM), Marseille
CHU de Caen, Caen
Centro Oncologico de Galicia, A Coruña
Gruppo Humanitas - Istituto Clinico Humanitas, Rozzano
Istituto Nazionale dei Tumori, Milan
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Complejo Hospitalario de Navarra (CHN), Pamplona
CHU Nantes, Nantes
Hospital Universitari i Politecnic La Fe de Valencia, Valencia
Highlands Oncology Group, Fayetteville
Vseobecna Fakultni Nemocnice, Prague
William Osler Health System, Brampton
Hospital Universitari Son Espases, Palma de Mallorca
Hospital Infanta Cristina (Hospital Universitario de Badajoz), Badajoz
Hospital Universitario Vall d'Hebron, Barcelona
Althaia Hospital, Manresa
Lead Sponsor
iTeos Belgium SA
INDUSTRY
iTeos Therapeutics
INDUSTRY